Cellular Immunotherapy—Highlights from TCT 2021

Ran Reshef; Pawel Muranski; Jeffrey S. Miller

doi:10.1016/j.jtct.2021.04.015

Cellular Immunotherapy—Highlights from TCT 2021

Ran Reshef, Pawel Muranski, Jeffrey S. Miller

Research output: Contribution to journal › Comment/debate › peer-review

Original language	English (US)
Pages (from-to)	527-532
Number of pages	6
Journal	Transplantation and Cellular Therapy
Volume	27
Issue number	7
Early online date	Apr 26 2021
DOIs	https://doi.org/10.1016/j.jtct.2021.04.015
State	Published - Jul 1 2021

Bibliographical note

Funding Information:
Financial disclosure: R.R. reports consulting fees or honoraria from Gilead, Novartis, BMS, Bayer, Atara, TScan, CareDx, and Regeneron and clinical trial support to Columbia University from Gilead, BMS, Bluebird Bio, Janssen, Vertex, Atara, Immatics, Adaptimmune, Bellicum, Incyte, Takeda, Pharmacyclics, Tmunity, Shire, and Precision Biosciences. P.M. reports consulting fees from Atara and AstraZeneca. J.S.M. consults for and holds stock in Fate and GT BioPharma and receives research funds from these companies. These interests have been reviewed and managed by the University of Minnesota in accordance with its conflict of interest policy. Financial disclosure: See Acknowledgments on page 531.

Publisher link

10.1016/j.jtct.2021.04.015

Find It

Find It at U of M Libraries

Cite this

@article{51485a67fdcc41df8c26236a0fcc833e,

title = "Cellular Immunotherapy—Highlights from TCT 2021",

author = "Ran Reshef and Pawel Muranski and Miller, {Jeffrey S.}",

note = "Funding Information: Financial disclosure: R.R. reports consulting fees or honoraria from Gilead, Novartis, BMS, Bayer, Atara, TScan, CareDx, and Regeneron and clinical trial support to Columbia University from Gilead, BMS, Bluebird Bio, Janssen, Vertex, Atara, Immatics, Adaptimmune, Bellicum, Incyte, Takeda, Pharmacyclics, Tmunity, Shire, and Precision Biosciences. P.M. reports consulting fees from Atara and AstraZeneca. J.S.M. consults for and holds stock in Fate and GT BioPharma and receives research funds from these companies. These interests have been reviewed and managed by the University of Minnesota in accordance with its conflict of interest policy. Financial disclosure: See Acknowledgments on page 531.",

year = "2021",

month = jul,

day = "1",

doi = "10.1016/j.jtct.2021.04.015",

language = "English (US)",

volume = "27",

pages = "527--532",

journal = "Transplantation and Cellular Therapy",

issn = "2666-6367",

publisher = "Elsevier BV",

number = "7",

}

TY - JOUR

T1 - Cellular Immunotherapy—Highlights from TCT 2021

AU - Reshef, Ran

AU - Muranski, Pawel

AU - Miller, Jeffrey S.

N1 - Funding Information: Financial disclosure: R.R. reports consulting fees or honoraria from Gilead, Novartis, BMS, Bayer, Atara, TScan, CareDx, and Regeneron and clinical trial support to Columbia University from Gilead, BMS, Bluebird Bio, Janssen, Vertex, Atara, Immatics, Adaptimmune, Bellicum, Incyte, Takeda, Pharmacyclics, Tmunity, Shire, and Precision Biosciences. P.M. reports consulting fees from Atara and AstraZeneca. J.S.M. consults for and holds stock in Fate and GT BioPharma and receives research funds from these companies. These interests have been reviewed and managed by the University of Minnesota in accordance with its conflict of interest policy. Financial disclosure: See Acknowledgments on page 531.

PY - 2021/7/1

Y1 - 2021/7/1

UR - http://www.scopus.com/inward/record.url?scp=85107120980&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85107120980&partnerID=8YFLogxK

U2 - 10.1016/j.jtct.2021.04.015

DO - 10.1016/j.jtct.2021.04.015

M3 - Comment/debate

C2 - 33915324

AN - SCOPUS:85107120980

SN - 2666-6367

VL - 27

SP - 527

EP - 532

JO - Transplantation and Cellular Therapy

JF - Transplantation and Cellular Therapy

IS - 7

ER -

Cellular Immunotherapy—Highlights from TCT 2021

Bibliographical note

Publisher link

Find It

Other files and links

Cite this